Gitasha Chand
Chief Tech/Sci/R&D Officer at RADIOPHARM THERANOSTICS LIMITED
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hong-Hoi Ting | M | - |
NanoMab Technology Ltd.
 NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 8 years |
| Thomas Tulip | M | 71 | 3 years | |
| Riccardo Canevari | M | - | 3 years | |
| Ian Turner | M | - | - | |
| Levente Meszaros | M | - |
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 2 years |
| Hester Larkin | F | - | 2 years | |
| Henry Ho | M | - |
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | 8 years |
| Paul Hopper | M | 68 | 3 years | |
| Vittorio Puppo | M | - | 2 years | |
| Scot Harper | M | 67 | 3 years | |
| Leila Alland | M | 61 | 2 years | |
| Nathan Jong | M | - | - | |
| David Mozley | M | - | - | |
| Sherin Al-Safadi | M | - | 1 years | |
| Antje Wegener | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Baker | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Australia | 14 | 87.50% |
| China | 3 | 18.75% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gitasha Chand
- Personal Network
